title: Haemolytic uraemic syndrome associated with OKT3.
authors.forename: G
authors.initials: G
authors.lastname: Morris-Stiff
authors.forename: M
authors.initials: M
authors.lastname: Evans
authors.forename: K
authors.initials: K
authors.lastname: Baboolal
authors.forename: V
authors.initials: V
authors.lastname: Balaji
authors.forename: R
authors.initials: R
authors.lastname: Moore
authors.forename: A
authors.initials: A
authors.lastname: Jurewicz
authors.forename: R
authors.initials: R
authors.lastname: Lord
mesh_terms: D005260:Female; D006463:Hemolytic-Uremic Syndrome / Q000209:etiology* / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007511:Ischemia / Q000473:pathology; D007668:Kidney / Q000098:blood supply / Q000473:pathology; D016030:Kidney Transplantation; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000009:adverse effects*; D011183:Postoperative Complications / Q000209:etiology*; D016559:Tacrolimus / Q000627:therapeutic use
chemical_list: D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016559:Tacrolimus